{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-013840","form_type":"8-K","ticker":"BTAI","cik":"0001720893","company_name":"BioXcel Therapeutics, Inc.","filed_at":"2026-02-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.000744+00:00","generated_at":"2026-05-16T03:04:42.118977+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"BioXcel updates IGALMI at-home opportunity: up to 86M annual episodes, sNDA pending","bullets":["Updated market assessment for IGALMI at-home use identifies up to 86M addressable annual episodes, up from prior 57-77M estimate.","sNDA seeking FDA approval for at-home use submitted last month; assessment based on SERENITY At-Home study and market research.","Prescribers project using IGALMI in ~70% of schizophrenia/bipolar disorder patients; patients expect use in ~80% of agitation episodes.","Claims data: ~2.3M treated patients experience frequent acute agitation at home; up to 1.8M may be eligible for IGALMI.","Payers indicated expectations for broad formulary coverage with standard adjudication controls; prescribers report moderate-high unmet need."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-013840","json":"https://secwatch.observer/filing/0001104659-26-013840.json","markdown":"https://secwatch.observer/filing/0001104659-26-013840.md","text":"https://secwatch.observer/filing/0001104659-26-013840.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1720893/000110465926013840/0001104659-26-013840-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1720893/000110465926013840/tm266150d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T03:04:42.118977+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}